# NATIONAL MATERIALS AND MANUFACTURING BOARD

# **Roundtable on Biomedical Engineering Materials and Applications**

#### **Agenda**

The National Academies
Keck Center
500 5<sup>th</sup> Street NW, Washington, DC 20001
Room 208
March 8-9, 2020

"Issues and Opportunities Regarding the Availability of Biomaterials and Services for the Medical Device Industry"

### Sunday, March 8

Working Dinner: Carmine's Restaurant, 425 7<sup>th</sup> St., NW. Washington, D.C. (Seating @ 6:00 p.m.)

#### **After Dinner Talk:**

"Overview of Commercial Polymers (Considered/Used/Removed) for Medical Devices over 50 Years" Speaker: Art Coury, BEMA Co-Chair

## Monday, March 9

8:00-8:30 am	Breakfast in meeting room
8:30-9:10 am	"Status and Potential Value of a Materials for Medical Devices Database" Speaker: Mike Helmus, Consultant
9:10-9:50 am	"Have a Heart - The Case of "Biomer": Supply Pathway From Materials Supplier Device Manufacturer (DuPont – J&J (Ethicon) – Syncardia): Potential Materials Assurance Strategy"  Speaker: Marvin Slepian (U. of Arizona, Founder of Syncardia)
9:50-10:05 am	Break
10:05-10:45 am	"Biomaterials Standards in Regard to Supply Chain Issues" Speaker: Carl Simon, NIST
10:45-11:25 am	"Material and Service Outsourcing Issues in the Medical Device Supply Chain" Speaker: Larry Thatcher, TESco Associates
11:25- 12:05 am	"Drug Shortages: Root Causes and Potential Solutions" Speaker: Emily Thakur, FDA

12:05-12:45 pm	Lunch
12:45- 1:25 pm	"Biomaterial Access Assurance Act of 1988: Issues and Developments Prior and Subsequent to Passage" Speaker: Scott McNamee, FDA
1:25-2:05 pm	"Corporate Perceptions of the Risk of Developing, Providing, and Controlling Distribution of Biomaterials: The Perspectives of a 33-year Dow Corning/Dow Chemical/Dupont Veteran" Speaker: Jim Curtis, DuPont
2:05-2:20 pm	Break
2:20-3:00 pm	"Biomaterials Supply Issues of a Medical Device Leader: Medtronic: Biomaterials Customer and Biomaterials Developer" Speaker: Patrick F. Walker, Medtronic
3:00-3:40 pm	"Metallic Biomaterials Safety and Potential to Affect Availability: Risk vs. Reward Considerations"  Speaker: Bob Hastings, Johnson and Johnson
3:40-3:55 pm	Break
3:55-4:15 pm	Summary by Rapporteur Elizabeth Bielski, FDA
4:15-4:45 pm	Planning and Close